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Despite the substantial public health impact of prostate cancer,
little is known about its aetiology. Improved knowledge of the
natural history and genetic basis of prostate cancer would be
important to develop prevention, screening, early diagnosis and
intervention strategies. Recently, several loci have been implied 
in predisposing to prostate cancer by genetic linkage studies 
in cancer families. These include the HPC-1 locus at 1q24–q25
(Smith et al, 1996), HPC2 at 1q42–q43 (Berthon et al, 1998),
HPCX at Xq27–q28 (Xu et al, 1998), HPBC at 1p36 (Gibbs 
et al, 1999), and loci at 20q13 (Berry et al, 2000), 11p (Gibbs et al,
2000) and 16q (Suarez et al, 2000). Exploration of the genetic
basis of prostate cancer susceptibility by linkage analysis is chal-
lenging due to genetic heterogeneity (the large number of loci
involved), due to incomplete penetrance of germline mutations
and due to clustering of sporadic prostate cancer. Another
approach to identify genetic risk factors is association, the study of
the frequencies of polymorphisms in candidate genes between test
and control populations. Several polymorphisms have been
suggested to be associated with prostate cancer. These include the
CAG and GGC repeats in the androgen receptor (AR) gene (Irvine
et al, 1995; Giovannucci et al, 1997), as well as polymorphisms in
the vitamin D receptor (Taylor et al, 1996; Ingles et al, 1997), 17-
hydroxylase cytochrome P450 gene (CYP17) (Lunn et al, 1999),
3b-hydroxysteroid dehydrogenase type II (HSD3B2) (Devgan 
et al, 1997), BRCA1 (Ford et al, 1994) and BRCA2 (The Breast
Cancer Linkage Consortium, 1999) as well as the 5a-reductase
type II (SRD5A2) (Reichardt et al, 1995; Makridakis et al, 
1997). 
SRD5A2 gene encodes for a critical enzyme catalysing the intra-
prostatic conversion of testosterone, the most abundant androgen
in the serum, to more potent 5a-dihydrotestosterone (DHT). DHT
binds to the androgen receptor with high affinity and leads to
transactivation of androgen targets. Since the development and
growth of prostate cancer is dependent on androgens (Cunha et al,
1987), genetic variations that affect the SRD5A2 enzyme activity
could be associated with the risk of developing prostate cancer. A
TA-dinucleotide repeat polymorphism at the 3¢ UTR of SRD5A2
(Davis and Russell, 1993; Reichardt et al, 1995; Kantoff et al,
1997) and a valine to leucine substitution at codon 89 (Makridakis
et al, 1997; Febbo et al, 1999; Lunn et al, 1999) have not been
found to be associated with prostate cancer. A third polymor-
phism, alanine to threonine substitution at codon 49 (A49T) results
in a variant 5-a-reductase enzyme with a Vmax of about 5 times that
of the wild enzyme (Ross et al, 1998; Makridakis et al, 1999).
Makridakis et al (1999) recently reported that the A49T variant
was more common among 216 African-American and 172
Hispanic prostate cancer patients than in the corresponding ethi-
cally matched controls. The authors suggested that up to 8% of the
clinically advanced prostate cancers in these populations could be
attributable to this genetic variant (Makridakis et al, 1999). This
finding is supported by the findings of Jaffe et al (2000), who
reported that men who carry the A49T variant have prostate
tumours that are more likely to exhibit extracapsular extension and
higher pTNM stage than men who do not carry this variant. In
addition, the A49T variant was overrepresented in men with poor
prognosis based on a combined analysis of their PSA level,
Gleason score, and TNM stage, or on a combined analysis of their
margin status and Gleason score (Jaffe et al, 2000). 
Here, we compared the prevalence of A49T mutation among
Finnish prostate cancer patients and population controls. The
advantage of the Finnish population is its genetic homogeneity.
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Therefore, ethnic and other population differences are likely to be
less problematic than in case–control studies of more admixed
populations. 
SUBJECTS AND METHODS 
We collected genomic DNA specimens from 449 consecutively
diagnosed prostate cancer patients and 223 benign prostate hyper-
plasia cases. These specimens came from the Tampere University
Hospital, which serves as the local referral area for prostate cancer
treatment. We also analysed 111 samples from 94 Finnish prostate
cancer families from the whole Finland with at least 2 affected
first-degree relatives. As controls, we acquired DNA specimens
from 516 anonymous, unselected healthy male blood donors from
Tampere region and 72 samples from autopsies in the Tampere
University Hospital from males aged >65 years who were deter-
mined to be cancer-free. The study was based in a population-
based sampling of prostate cancer patients and healthy blood
donors and did not correspond to a classical case–control study.
Taken together with the use of the Finnish population in this study,
the typical problems associated with case–control studies should
be avoided. 
Written informed consent was obtained from all living patients
and their family members, and research protocols were approved
by the Ethical Committee of the Tampere University Hospital. The
patients’ family histories for malignancies were initially obtained
from family questionnaires. All prostate cancer diagnoses were
confirmed through medical records or from the Finnish Cancer
Registry. 
WHO tumour grading was available in 95% of the sporadic
cases. Gleason score is not routinely used in Finland and was
determined in 67% of the cases. The T-stage (T1–T4) was
obtained in 92%, and M-stage in 81% of the cases. The M-stage
was based on a bone scan in all evaluable cases. 
Samples were first analysed by ASO-hybridization and later 
by minisequencing as this method was adapted in our laboratory.
A large fraction of samples were analysed with both methods to
ensure that the results were identical in all cases. 
Allele-specific oligonucleotide hybridization 
Genomic DNA was amplified using primers 5¢-ACTGGCCTTG-
TACGTCGC-3¢ and 5¢-AGGGCAGTGCGCTGCACT-3¢. Amplific-
ation reactions and conditions were as followed: 100 ng of DNA,
200 nM of both primers, 200 mM of each deoxy-NTP, 1.75 mM
MgCl2, and 1.5 U AmpliTaqGold™DNA Polymerase (Perkin-
Elmer) in a final volume of 50 ml; at 95˚C for 10 min, followed by
35 cycles of 95˚C 1 min, 58˚C for 1 min, and 72˚C for 1 min, with
a 5 min extension at 72˚C after the last cycle. Mutation detection
was done using allele specific oligonucleotide (ASO) hybridiza-
tion as described by Friedman et al (1995) with these exceptions:
filters were prewetted in and wells washed with 0.4 M Tris-
HCl pH 7.5, probes were end-labelled with 32P at 37˚C for 3 h 
by Terminal Deoxynucleotidyl Transferase (Amersham Life
Science), and hybridizations were performed at 54˚C. ASOs 
used in hybridizations were: 5¢-GCCTGCCAGCCCGCGCCG-3¢
(wild-type) and 5¢-GCCTGCCAACCCGCGCCG-3¢ (mutation). A
mutation positive control as well as a negative control of the PCR
reaction was included in each ASO hybridization. 
Minisequencing 
A 174 bp fragment was first amplified as follows: 100 ng of DNA,
200 nM of both primers, 200 mM of each deoxy-NTP, 2.5 mM
MgCl2, and 2.5 U AmpliTaqGold™DNA Polymerase (Perkin-
Elmer) in a final volume of 75 ml; at 95˚C for 10 min, followed by
35 cycles of 95˚C 1 min, 71˚C for 1 min, and 72˚C for 1 min, with
a 5 min extension at 72˚C after the last cycle. Primers for PCR
were 5¢biotin-GCGAAGCCCTCCGGCTACGGGA-3¢ and 5¢-
CGCGGGCACCCGCGAAGGAAGGC-3¢. Minisequencing was
performed as described by Syvänen (1998) with a detection primer
5¢-CAGGAACCAGGCGGCGCGGG-3¢. 
Mutation positive ASO and minisequencing results were
confirmed by sequencing with ABI PRISM 310 Genetic Analyser
(Perkin-Elmer) as recommended by the manufacturer. Primers
used in sequencing were the same as those in PCR. 
Statistical analysis 
Statistical analyses were performed using the GraphPad InStat
version 2.04a (GraphPad Software, CA, USA). Categorical vari-
ables were compared with the Fisher’s exact test and c2 (chi
square) test for independence and continuous variables were
analysed with Student’s t-test. In addition, odds ratio (OR) and its
95% confidence intervals (95% CI) were calculated. All the tests
were two-tailed. 
RESULTS 
The frequency of the A49T substitution was 6.0% in 449 prostate
cancer patients and 5.8% among the population-based controls
(Table 1, OR = 1.04 for cancer, 95% CI = 0.62–1.76, P = 0.89). As
compared to sporadic prostate cancer, the frequency of the A49T
was slightly lower in 94 prostate cancer families (5.3%), whereas
patients with benign prostatic hyperplasia had slightly higher
frequency (6.3%). However, none of these differences were statis-
tically significant. The prevalence of the A49T among the autopsy
samples was 4.2% (3/72) and 6.0% (31/516) among the 516 blood
donors. Because of the small number of the autopsy samples, we
combined data for all donors as controls in the statistical analysis. 
The results were also analysed separately for patients with
metastatic (M1) and non-metastatic (M0) prostate cancer, as well
as for patients with different T-stages, Gleason score and WHO
grades (Table 2). No statistically significant associations emerged.
In fact, there was a tendency for A49T substitution to be more
common among the localized or lower grade cancers as defined
either by a T1–T2 status, M0 status, Gleason score 2–6 or 
WHO grade I. However, none of these trends were statistically
significant. The mean age of diagnosis did not differ between
patients with A49T mutation (67.8 years, 27/449) compared to
non-carrier patients (68.3 years, 422/449). The distribution 
for A49T genotype among population controls was in the
Hardy–Weinberg equilibrium. 
DISCUSSION 
Linkage studies published in prostate cancer have not shown any
positivity at 2p23, the chromosomal location of the SRD5A2 gene.
However, Makridakis et al (1999) recently documented in a case–
control association study that the A49T mutation in the SRD5A2
gene may increase the risk of prostate cancer by a factor of 2.5 to1346 N Mononen et al 
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3.28, in Hispanic and in the African-American populations. The
risk for clinically advanced disease were shown to be 3.6-fold and
7.2-fold, respectively (Makridakis et al, 1999). The authors esti-
mated that A49T could account for as much as 8% of clinically
significant prostate cancers. Jaffe et al (2000) obtained a similar
association for more aggressive disease among the Caucasian pros-
tate cancer patients. In our study involving a total of 1371 subjects,
the A49T SRD5A2 mutation turned out to be equally common in
population controls (5.8%), patients with benign prostatic hyper-
plasia (6.3%), and those with prostate cancer patients (6.0%).
Stratification by T(N)M status, Gleason score or WHO grade did
not reveal any subgroups with a significantly increased risk. Our
results therefore do not support the findings by Makridakis and co-
workers (1999) or those of Jaffe et al (2000). Finally, in our study
the frequency of A49T was less common in index patients selected
from 94 prostate cancer families as compared to ‘sporadic’ family-
history-negative patients. If the A49T had a strong influence on the
predisposition to prostate cancer, one would expect to find a higher
frequency in the patients with positive family history. This finding
further argues against the prominent role of A49T as a cause of
prostate cancer in the Finnish population. 
The differences between the studies may be explained by a
number of factors. First, genetic risk factors may differ in different
populations and can be influenced by environmental effects.
Second, allele association studies are often affected by ethnic and
other differences between the test and control groups that are unre-
lated to disease. Our study was based on materials from one
university hospital region, which serves as the major regional
referral centre for prostate cancer treatment in the area. In the
Finnish health care system, patients in such major centres for
cancer treatment reflect a representative unbiased sample of the
entire population. The same is true for blood donors collected from
the same hospital. The Finnish population, and particularly regions
within the country, are genetically very homogeneous (Peltonen,
1997), and therefore ideal for allele association studies. Third,
genetic associations often occur by chance. The number of pros-
tate cancer cases analysed in our study was >2-fold higher than in
either of the 2 populations studied by Makridakis et al (1999) or by
Jaffe et al (2000). However, both study populations are still rela-
tively small and larger studies are warranted. The main difference
between our study and that of Makridakis et al (1999) is that the
frequency of the AT/TT genotype in the Finnish control population
(5.8%) was substantially higher than in the African-American
(1.5%) and Hispanic controls (3.5%). The small group of samples
from autopsy obtained from >65-year-old cancer-free Finnish men
showed a 4.2% AT/TT genotype frequency. The results suggest
that genotype frequencies in the control populations used in these
studies varied more than those in the cancer patients. The AT/TT
genotype was approximately equally common (range from 6.0% to
7.3%) among the prostate cancer patients in the different racial/
ethnic groups in the 3 studies. The different results probably
cannot be explained by differences in methods used to screen the
A49T mutation. 
Although sex hormones are clearly involved in the prostate
carcinogenesis, the role of genetic variation in the genes
comprising the steroid biogenesis pathway remains unclear. We
Table 1 SRD5A2 genotype frequencies in 4 groups of Finnish patients and population controls 
Prevalence of Odds ratioa 95% confidence P valuea
A49T (%) interval 
Sporadic prostate cancer  27/449 (6.0) 1.04 0.62–1.76 0.89 
Familial prostate cancer 5/94 (5.3) 0.92  0.35–2.40 1.00 
Benign prostatic hyperplasia 14/223 (6.3) 1.09  0.57–2.08 0.87 
Controls 34/588 (5.8) – –  – 
aAs compared to controls (blood donors and autopsy samples). 
Table 2 Association of SRD5A2 genotype with clinicopathological characteristics of the prostate cancer patients 
A/T or T/T A/A Prevalence of  Chi square P value 
A49T (%) 
T-stage 0.96 0.62 
T1–T2 14 200 6.5 
T2–T4 10 191 5.0 
Unknown 3 31 8.8 
M-stage 0.94 0.62 
M0 20 274 6.8 
M1 3 65 4.4 
Unknown 4 83 4.6 
Gleason score 1.83 0.40 
2–6 15 182 7.6 
7–10 4 99 3.9 
Unknown 8 141 5.4 
WHO Grade 3.11 0.37 
I 4 90 4.3 
II 17 237 6.7 
III 3 74 3.9 
Unknown 3 21 12.5 SRD5A2 gene mutation A49T 1347
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conclude that the A49T variant of the SRD5A2 gene is not strongly
associated with prostate cancer development or progression in the
Finnish population. 
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